BellRing Brands (BRBR)
(Delayed Data from NYSE)
$49.67 USD
-1.56 (-3.05%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $49.64 -0.03 (-0.06%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$49.67 USD
-1.56 (-3.05%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $49.64 -0.03 (-0.06%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Zacks News
Here's Why You Should Hold on to Hill-Rom (HRC) for Now
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why BellRing Brands (BRBR) Could Beat Earnings Estimates Again
by Zacks Equity Research
BellRing Brands (BRBR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is BellRing Brands (BRBR) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
Here's Why You Should Retain CVS Health (CVS) Stock For Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on growth in the company's specialty digital solutions and a bullish 2021 outlook.
Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise
by Zacks Equity Research
Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.
Cardiovascular Systems (CSII) Treats 1st Patient With ViperCross
by Zacks Equity Research
Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.
Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers
by Zacks Equity Research
Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).
Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio
by Zacks Equity Research
Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.
NEOGEN (NEOG) Inks Genomic Selection Deal With Hendrix
by Zacks Equity Research
Hendrix Genetics with the help of NEOGEN's (NEOG) Genomics will be able to genotype the elite animals in the population.
Here's Why You Should Invest in Quest Diagnostics (DGX) Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.
New Strong Buy Stocks for September 29th
by Zacks Equity Research
BRBR, CNHI, DLA, FNF, and RM have been added to the Zacks Rank #1 (Strong Buy) List on September 29, 2021.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) owing to new product flow and strong market share gain across the company's businesses.
Medtronic (MDT) Hugo RAS System Used for 1st Clinical Procedure
by Zacks Equity Research
Medtronic's (MDT) Hugo RAS system is a modular, multi-quadrant platform intended for a broad range of soft-tissue procedures.
IDEXX (IDXX) CAG Placement Grows Globally Amid Cost Woes
by Zacks Equity Research
IDEXX's (IDXX) global reference lab revenues are growing organically, reflecting growth in the United States and the international markets.
Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.
NuVasive (NUVA) Expands Training Opportunities With New Center
by Zacks Equity Research
NuVasive's (NUVA) East Coast Experience Center reflects the company's commitment to provide best quality surgeon education and training to enhance the standard of patient care in spine surgery.
CVS Health (CVS) Retail Business Grows Despite Cost Pressure
by Zacks Equity Research
CVS Health's (CVS) retail business sees solid rebound in front-store sales with strength across all categories.
SmileDirectClub (SDC) to Boost Europe Presence, Enter France
by Zacks Equity Research
SmileDirectClub (SDC) since its foray into Europe in 2019 has been seeing remarkable market penetration of its oral care products.
Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.
Medtronic (MDT) Starts Pediatric Trial for Scoliosis Treatment
by Zacks Equity Research
Medtronic's (MDT) BRAIVE IDE study will assess the safety and efficacy of growth modulation system in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis.
Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.
New Strong Buy Stocks for September 22nd
by Zacks Equity Research
BRBR, CNHI, MCFT, CC, and UFI have been added to the Zacks Rank #1 (Strong Buy) List on September 22, 2021.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on robust second-quarter 2021 performance and raised guidance.